HUP0202367A2 - FAP-aktivált tumorellenes peptidek, eljárás előállításukra, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents

FAP-aktivált tumorellenes peptidek, eljárás előállításukra, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk

Info

Publication number
HUP0202367A2
HUP0202367A2 HU0202367A HUP0202367A HUP0202367A2 HU P0202367 A2 HUP0202367 A2 HU P0202367A2 HU 0202367 A HU0202367 A HU 0202367A HU P0202367 A HUP0202367 A HU P0202367A HU P0202367 A2 HUP0202367 A2 HU P0202367A2
Authority
HU
Hungary
Prior art keywords
group
amino
fap
pharmaceutical compositions
groups
Prior art date
Application number
HU0202367A
Other languages
English (en)
Inventor
Raymond Armand Firestone
Pilar Garin-Chesa
Dietmar Leipert
Martin Lenter
Jürgen Mack
John Edward Park
Stefan Peters
Wolfgang J. Rettig
Leila A. Telan
Original Assignee
Boehringer Ingelheim Pharma Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Kg filed Critical Boehringer Ingelheim Pharma Kg
Publication of HUP0202367A2 publication Critical patent/HUP0202367A2/hu
Publication of HUP0202367A3 publication Critical patent/HUP0202367A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

kPage=A;BrkToNext=N;>(57) A találmány tárgyát az általános képletűvegyületek - ahol R1 amino-alkanoil- vagy oligopeptidoil-csoport,amelynek amino-terminális aminocsoportjához adott esetben egy blokkolócsoport kapcsolódik; Ra és Rb a kettőjük közötti N-C csoporttal együttegy adott esetben szubsztituált és adott esetben benzo- vagyciclohexanocsoporttal kondenzált heterogyűrűt képez, amelyben egy vagykét metiléncsoportot adott esetben -NH-csoport, oxigén- vagy kénatomhelyettesít; R9 hidrogénatom, alkil-, cikloalkil-, aril- vagyheteoaril-csoport; és Cyt' egy citotoxikus vagy citosztatikus vegyületmaradéka; azzal a fenntartással, hogy a háromnál több aminosavegységettartalmazó oligopeptidoilcsoportokban a Gln-csoport közvetlenül csak aSer-től eltérő csoportokhoz kapcsolódhat - és előállításuk, továbbátumorok kezelésére szolgáló gyógyszerkészítményekben prodrugként valóalkalmazásuk képezi. Ó
HU0202367A 1999-05-14 2000-05-11 Fap-activated anti-tumor peptides, process for their preparation pharmaceutical compositions comprising thereof and their use HUP0202367A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13413699P 1999-05-14 1999-05-14

Publications (2)

Publication Number Publication Date
HUP0202367A2 true HUP0202367A2 (hu) 2002-11-28
HUP0202367A3 HUP0202367A3 (en) 2003-10-28

Family

ID=22461925

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202367A HUP0202367A3 (en) 1999-05-14 2000-05-11 Fap-activated anti-tumor peptides, process for their preparation pharmaceutical compositions comprising thereof and their use

Country Status (28)

Country Link
US (1) US6613879B1 (hu)
EP (1) EP1180116A2 (hu)
JP (1) JP3607201B2 (hu)
KR (1) KR20020030270A (hu)
CN (1) CN1213058C (hu)
AR (1) AR033792A1 (hu)
AU (1) AU777521B2 (hu)
BG (1) BG106096A (hu)
BR (1) BR0010564A (hu)
CA (1) CA2369933A1 (hu)
CO (1) CO5170516A1 (hu)
CZ (1) CZ20014097A3 (hu)
EA (1) EA005204B1 (hu)
EE (1) EE200100600A (hu)
HK (1) HK1048642B (hu)
HU (1) HUP0202367A3 (hu)
IL (1) IL145798A0 (hu)
MX (1) MXPA01011401A (hu)
MY (1) MY125939A (hu)
NO (1) NO20015536L (hu)
NZ (1) NZ516075A (hu)
PL (1) PL351680A1 (hu)
SK (1) SK16452001A3 (hu)
TW (1) TWI248444B (hu)
UA (1) UA73506C2 (hu)
WO (1) WO2000071571A2 (hu)
YU (1) YU80901A (hu)
ZA (1) ZA200109151B (hu)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2401873A1 (en) 2000-03-15 2001-09-20 Robert A. Copeland Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
GB0027551D0 (en) * 2000-11-10 2000-12-27 Boehringer Ingelheim Pharma Anti-tumor compounds
GB0027552D0 (en) * 2000-11-10 2000-12-27 Boehringer Ingelheim Pharma Anti-tumor compounds
CA2447470A1 (en) * 2001-05-09 2002-11-14 Newbiotics, Inc. Peptide deformylase activated prodrugs
US7091186B2 (en) * 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
EP1333033A1 (en) * 2002-01-30 2003-08-06 Boehringer Ingelheim Pharma GmbH & Co.KG FAP-activated anti-tumor compounds
US20030211979A1 (en) * 2002-01-30 2003-11-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg FAP-activated anti-tumor compounds
CA2482029A1 (en) * 2002-04-18 2003-10-30 Maria V. Sergeeva Peptide deformylase activated prodrugs
EP1506221A2 (en) * 2002-05-10 2005-02-16 Boehringer Ingelheim Pharma GmbH & Co.KG Fap-activated anti-tumor prodrugs
US20040033957A1 (en) * 2002-05-10 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg FAP-activated anti-tumor prodrugs
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
EP1585751A4 (en) 2002-11-14 2008-08-13 Celmed Oncology Usa Inc PEPTIDE DEFORMYLASE-ACTIVATED PRODRUGS
GB0310593D0 (en) * 2003-05-08 2003-06-11 Leuven K U Res & Dev Peptidic prodrugs
JP2007511467A (ja) 2003-05-14 2007-05-10 タケダ サン ディエゴ インコーポレイテッド ジペプチジルペプチダーゼインヒビター
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1753730A1 (en) 2004-06-04 2007-02-21 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2006073167A1 (ja) * 2005-01-07 2006-07-13 Ono Pharmaceutical Co., Ltd. ピロリジン誘導体
EP1943257A2 (en) * 2005-05-19 2008-07-16 Genentech, Inc. Fibroblast activation protein inhibitor compounds and methods
EP1963537A4 (en) * 2005-12-14 2009-11-11 Ludwig Inst For Cancer Res Ltd METHOD FOR DIAGNOSING RHEUMATOID ARTHRITIS BY DETERMINING FIBROBLASTIC SYNOVIOCYTES FOR FIBROBLAST ACTIVATION PROTEIN
US20100047170A1 (en) * 2006-01-05 2010-02-25 Denmeade Samuel R Peptide Prodrugs
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2008005479A2 (en) * 2006-07-06 2008-01-10 University Of Wyoming Charge reversible polymers
US20100184706A1 (en) * 2007-03-20 2010-07-22 Bachovchin William W Fap-activated chemotherapeutic compounds, and methods of use thereof
JP5781930B2 (ja) * 2008-09-12 2015-09-24 カディラ ファーマシューティカルズ リミテッド 新規なジペプチジルペプチダーゼ（ｄｐ−ｉｖ）化合物
US9062094B2 (en) 2010-01-22 2015-06-23 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
EP2525829A1 (en) 2010-01-22 2012-11-28 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
US20150335761A1 (en) * 2012-02-16 2015-11-26 Raymond Firestone Compositions and methods for contraception
AU2013369261B2 (en) 2012-12-28 2018-08-09 Cobiores Nv Minimally toxic prodrugs
JP6250710B2 (ja) * 2013-04-19 2017-12-20 曁南大学 ビンブラスチン誘導体の調製方法
SI3066091T1 (sl) * 2013-11-05 2019-09-30 Astrazeneca Ab NMDA antagonist predzdravila
PL3154594T3 (pl) 2014-06-13 2023-10-09 Bach Biosciences, Llc Środki terapeutyczne aktywowane FAP i związane z nimi zastosowania
US9737556B2 (en) 2014-06-13 2017-08-22 Trustees Of Tufts College FAP-activated therapeutic agents, and uses related thereto
CN105524141B (zh) * 2015-11-12 2019-11-26 中山大学 一种FAPa激活式肿瘤诊断多肽磁珠复合物的制备与应用
EP3222292A1 (en) 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Amanitin conjugates
CN107043456B (zh) * 2017-04-19 2019-05-17 川北医学院 对氧环己酮与l-苯丙氨酸氮芥共聚物及其应用
CN110128501A (zh) * 2019-05-21 2019-08-16 北京海美源医药科技有限公司 一种靶向fap酶的喜树碱类化合物及其制备方法和应用
CN110128506B (zh) * 2019-05-22 2021-03-30 中国药科大学 一种寡肽及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3915800A (en) * 1972-03-30 1975-10-28 Kelco Co Polysaccharide and bacterial fermentation process for its preparation
FR2546163B1 (fr) 1983-05-16 1987-10-09 Centre Nat Rech Scient Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application
US5047401A (en) * 1985-09-09 1991-09-10 Board Of Regents, The University Of Texas System Use of dipeptide alkyl esters to treat GVHD
EP0255341B1 (en) 1986-07-29 1993-02-03 Sunstar Kabushiki Kaisha Reagent for testing periodontal diseases
US5776892A (en) * 1990-12-21 1998-07-07 Curative Health Services, Inc. Anti-inflammatory peptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5866679A (en) 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
DE19512484A1 (de) * 1995-04-04 1996-10-17 Bayer Ag Kohlenhydratmodifizierte Cytostatika
WO1997014416A1 (en) 1995-10-18 1997-04-24 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
EP0914123A4 (en) 1996-05-29 2000-10-11 Prototek Inc THALIDOMIDE PRODUCTS AND METHODS OF USING SAID PRODUCTS AS T CELL MODIFIERS
US5952294A (en) 1996-07-31 1999-09-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptidyl prodrugs and methods of making and using the same
WO1998013059A1 (en) 1996-09-27 1998-04-02 Bristol-Myers Squibb Company Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
DE19640970A1 (de) * 1996-10-04 1998-04-16 Bayer Ag Modifizierte Cytostatika
ES2342637T3 (es) 1998-12-11 2010-07-09 Medarex, Inc. Compuestos profarmacos y procedimiento para su preparacion.
JP2002542304A (ja) 1999-04-28 2002-12-10 ベクトレイムド インコーポレイテッド 酵素的に活性化された重合薬物接合体

Also Published As

Publication number Publication date
JP3607201B2 (ja) 2005-01-05
EA200101155A1 (ru) 2002-10-31
JP2003500417A (ja) 2003-01-07
BG106096A (bg) 2002-05-31
EA005204B1 (ru) 2004-12-30
CN1213058C (zh) 2005-08-03
AU6559100A (en) 2000-12-12
WO2000071571A2 (en) 2000-11-30
MY125939A (en) 2006-09-29
BR0010564A (pt) 2002-02-19
IL145798A0 (en) 2002-07-25
NO20015536D0 (no) 2001-11-13
EP1180116A2 (en) 2002-02-20
CA2369933A1 (en) 2000-11-30
HK1048642B (zh) 2005-10-28
YU80901A (sh) 2005-07-19
NZ516075A (en) 2004-03-26
WO2000071571A3 (en) 2001-09-07
US6613879B1 (en) 2003-09-02
TWI248444B (en) 2006-02-01
KR20020030270A (ko) 2002-04-24
HK1048642A1 (en) 2003-04-11
WO2000071571A8 (en) 2002-03-07
CZ20014097A3 (cs) 2002-02-13
HUP0202367A3 (en) 2003-10-28
CO5170516A1 (es) 2002-06-27
NO20015536L (no) 2002-01-10
SK16452001A3 (sk) 2002-03-05
ZA200109151B (en) 2002-12-17
EE200100600A (et) 2003-02-17
UA73506C2 (en) 2005-08-15
MXPA01011401A (es) 2002-06-04
PL351680A1 (en) 2003-06-02
CN1374969A (zh) 2002-10-16
AU777521B2 (en) 2004-10-21
AR033792A1 (es) 2004-01-07

Similar Documents

Publication Publication Date Title
HUP0202367A2 (hu) FAP-aktivált tumorellenes peptidek, eljárás előállításukra, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0203638A2 (hu) Béta2-Adrenerg receptor agonista hatóanyagok és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0302474A2 (hu) Terápiásan hatásos tropánszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0303756A2 (hu) 1-Aril- vagy 1-alkilszulfonil-heterociklobenzazolok és eljárás ezek elõállítására és ezeket tartalmazó gyógyszerkészítmények
SE9902987D0 (sv) Novel compounds
SE0102438D0 (sv) New compounds
HUP0402360A2 (hu) Poliaminok alkalmazása progenitor sejtek és/vagy őssejtek számának növelésére alkalmas gyógyszerkészítmény előállítására
KR970042553A (ko) 캠프토테신 유도체
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
HUP0002454A2 (hu) D-Vitamin-molekularésszel rendelkező konjugátumok és ilyen konjugátumokat tartalmazó gyógyászati készítmények
HUP0004040A1 (hu) Antimikrobiális hatású pleuromutilinszármazékok, eljárás ezek előállítására, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
UA27100A1 (uk) Заміщеhі піроли, що мають активhість іhгібіторів протеіhкіhази с, а також їх фармацевтичhо прийhятhі кислотhо-адитивhі солі і фармацевтичhа композиція
NO20010995D0 (no) Cytotoksiske peptider modifisert med store eller lipofile rester
ATE254630T1 (de) Cyclosporine
HUP0102579A2 (hu) Antiangiogén hatású peptid gyógyszervegyületek, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
TW200503775A (en) Pharmaceutical composition and method for treating
AR006598A1 (es) "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación"
HUP0301817A2 (hu) Kahalalid-vegyületek, elżállításukra szolgáló eljárás, azokat tartalmazó gyógyászati készítmények és alkalmazásuk
HUP0002404A2 (hu) Aminosavszármazékok, hatóanyagként ezeket tartalmazó gyógyszerkészítmények, eljárás előállításukra és alkalmazásuk
DE69928093D1 (de) Kombinationspräparat enthaltend monozyten-abgeleitete zellen zur behandlung von neoplastischen oder infektiösen erkrankungen
HUP0100865A2 (hu) Meta-azaciklusos csoporttal N-szubsztituált amino-benzoesav-vegyületek és származékaik mint integrin antagonista hatóanyagok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
JP2013509389A5 (hu)
TR199802537T2 (xx) Peptit t�revleri.
ES8502417A1 (es) "un procedimiento para obtener de orina una fraccion que contiene un ingrediente antineoplastico de naturaleza peptidica".
HUP0001922A2 (hu) Pirazolo[4,3-c]-piridin származékok, ezeket tartalmazó inzulinrezisztencia elleni gyógyszerkészítmények, intermedierek és eljárás előállításukra

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees